|
First author | Year | Dose | Sample | Duration (w) | Number | Study design | Outcome measure | Results |
|
Woodman [117] | 2003 | 3800 mg EPA or 3700 mg DHA versus olive oil | Hypertensive type 2 patients | 6 | 30 | RCT-PG | EDD, EID | Unchanged EDD and EID |
|
Engler [118] | 2004 | 1200 mg n-3 PUFA versus control diet | Hypercholesterolemic children | 10 | 20 | RCT-PC | EDD, oxidative stress, inflammation | Improved EDD, unchanged oxidative stress and inflammation |
|
Ros [119] | 2004 | 1100–1700 mg n-3 PUFA versus Mediterranean diet | Hypercholesterolemic patients | 4 | 20 | RCT-PG | EDD, oxidative stress and CRP | Improved EDD, unchanged oxidative stress and inflammation |
|
Keogh [120] | 2005 | 4700 mg mg n-3 PUFA versus isocaloric high carbohydrate, saturated or monounsaturated fat enriched-diet | Healthy subjects | 4 | 40 | RCT-PG | EDD, CRP, inflammation | Improved EDD in all groups except in saturated fat enriched diet |
|
Prabodh Shah [121] | 2007 | 500 mg n-3 PUFA versus placebo | Healthy subjects | 2 | 26 | RCT-PC | EDD, EID | Improved EDD and EID |
|
Wright [122] | 2008 | 3000 mg n-3 PUFA versus standard therapy | Systemic lupus erythematosus patients | 24 | 56 | RCT-PG | EDD, oxidative stress | Improved EDD and oxidative stress |
|
Schiano [123] | 2008 | 1700–2000 mg versus standard therapy | Intermittent claudication patients | 13 | 32 | RCT-PG | EDD, inflammation | Improved EDD, inflammation unchanged |
|
Mindrescu [124] | 2008 | 4500 mg n-3 PUFA + rosuvastatin 10 g versus rosuvastatin 10 g | Dyslipidemic patients | 4 | 30 | RCT-PG | EDD, EID | Improved EDD and EID |
|
Rizza [125] | 2009 | 1700–2000 mg n-3 PUFA versus placebo | Offspring of type 2 diabetic subjects | 12 | 50 | RCT-PC | EDD, inflammation | Improved EDD and inflammation |
|
Wong [99] | 2010 | 4000 mg n-3 PUFA versus control (olive oil) | Type 2 diabetes mellitus | 12 | 97 | RCT-PG | EDD, CRP, renal function | Improved renal function; no effect on EDD or CRP |
|
Stirban [100] | 2010 | 2000 mg versus control (olive oil) | Type 2 diabetes mellitus | 6 | 34 | RCT-PC | Postprandial EDD | Improved postprandial EDD |
|
Sanders [58] | 2011 | 450–900 or 1800 mg n-3 PUFA versus placebo (refined oil) | Healthy subjects | 51 | 310 | RCT-PC | EDD | Unchanged EDD and EID |
|
Skulas-Ray [101] | 2011 | 850 or 3400 mg versus placebo | Moderate hypertriglyceridemia | 8 | 26 | RTC-PC | EDD, IL-6, CRP | No effect on EDD, IL-6, or CRP |
|
Moertl [103] | 2011 | 1000 or 4000 mg n-3 PUFA versus placebo | CHF | 12 | 43 | RCT-PC | LVEF, EDD, IL-6 | Improved LVEF, EDD, and IL-6 |
|
Haberka [104] | 2011 | 1000 mg n-3 PUFA versus control (standard diet and therapy) | Previous AMI | 12 | 40 | RCT-PG | EDD, EID | Improved EDD; EID unchanged |
|
Din [105] | 2013 | 2000 mg n-3 PUFA versus placebo | Cigarette smokers | 6 | 20 | RCT-PC | EDD, P-selectin, CD40L | Improved EDD and P selectin; CD40L unchanged |
|
Din [108] | 2013 | 2000 mg n-3 PUFA versus placebo | Previous AMI | 6 | 20 | RCT-PC | EDD, P-selectin, CD40L | No effect |
|